Annual Report Forms for Postmarketing Requirements
The FDA published the final guidance on annual status reports and other submissions for postmarketing requirements (PMRs). The reports are intended to facilitate submissions by drug and biological product application holders of complete and accurate information on PMRs and postmarketing commitments (PMCs) in a consistent format. These forms are expected to result in improved accuracy and timeliness of FDA’s identification and review of those submissions containing information on PMRs and PMCs. The guidance covers
- the purpose of each form,
- when to use these forms,
- how to submit these forms.
The guidance also explains where applicants will be able to find the forms and instructions.
Background
Applicants are required to provide the agency with an annual report on the status of each PMR and PMC conducted to assess clinical safety, clinical efficacy, clinical pharmacology, or nonclinical toxicology of a human drug and biological product until FDA notifies the applicant, in writing, that the PMR or PMC has been fulfilled or that the PMR or PMC is no longer feasible or would no longer provide useful information.
This annual status report (ASR) on PMRs and PMCs must include the progress of the PMR or PMC or the reasons for failing to conduct the requirement or commitment. The specific milestone dates set forth as part of a PMR / PMC for conducting and completing a PMR / PMC include the following:
- Draft protocol submission date
- Final protocol submission date
- Study/clinical trial completion date
- Final report submission date
More information is available in FDA's Guidance for Industry Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989.
Related GMP News
20.11.2024The EU Qualified Person - What's it all about?
13.11.2024Glossary of ICH Terms and Definitions published
02.10.2024MHRA: New Rules for Manufacturers and Wholesalers after Brexit
24.09.2024What is RCA (Root Cause Analysis)?
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)